Douglas Sites has joined Rosetta Genomics as its executive VP of sales and marketing, a newly created position. Sites will report to Kenneth Berlin, president and CEO of the company. Before Rosetta, Sites was VP of sales and marketing at Asuragen and prior to that director of sales-hematology and oncology at PLUS Diagnostics.
The New York Genome Center has named Carol Ashe its new chief business officer. She previously served as VP of corporate development for pharmaceutical firm Endo International, and prior to that was a partner at GlaxoSmithKline's venture capital fund, SR One. Ashe also led GSK's US corporate legal group, which supported M&A transactions and the business development legal transactions team.